Navigation Links
NeurogesX to Present at Susquehanna Financial Group's 2nd Annual SIGnificant Options in Healthcare Conference
Date:2/28/2008

SAN MATEO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, Chief Executive Officer, is scheduled to present to a panel focused on pain management at Susquehanna Financial Group's 2nd Annual SIGnificant Investment Options in Healthcare Conference. Mr. DiTonno is scheduled to present on Tuesday, March 4, 2008 in New York City.

Event: SIGnificant Investment Options in Healthcare Conference

Date: Tuesday, March 4, 2008

Time: 4:00 p.m. Eastern Time

Place: The W Hotel

541 Lexington Avenue at 49th Street

New York City, NY

An audio Web cast of the Company's presentations will be available by accessing the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements concerning future presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX The Ruth Group

Anthony DiTonno Investors / Media

(650) 358-3330 Stephanie Carrington / Jason Rando

aditonno@neurogesx.com (646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
2. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
3. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
4. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
5. Representative Greg Harris, Senator Jacqueline Collins, Senator Iris Martinez and Fellow State Legislators to Join Susan G. Komen for the Cure in Announcing Groundbreaking Legislation to Reduce Breast Cancer Disparities; Will Hold Press Conference Friday
6. Nationwide to Present at Citigroup Global Property CEO Conference
7. Urine protein may be present before hypertension diagnosis in at-risk adolescents
8. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. Ventas to Present at the Citi 2008 Global Property CEO Conference
10. Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference
11. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a unique ... buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle ... in all of its creations to help create a more traditional and natural approach ...
(Date:1/22/2017)... ... , ... Medical lab testing through hospitals and other traditional methods ... will take days to arrive to the end customer, having to travel through medical ... lab tests, bypassing the cost and delay of traditional means. Now all employees of ...
(Date:1/21/2017)... Boca Raton, FL (PRWEB) , ... January 21, 2017 , ... ... from Germany, announced it is bringing its product to the United States as part ... perfected over the last 25 years, Alcovit aims to reduce the productions of nasty ...
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at ... Oat is recognized globally as one of the healthiest cereals, XieQingkui, the founder of ... a move to sow the seed of good karma. Buddhism spirit featuring benevolence and ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica ... Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home 2017,” ... community. “Coming Home 2017” will be held on Friday January 27 through ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
(Date:1/19/2017)... 2017 Pfizer joins Astex, ... Therapeutics Consortium   Major research investment ...   The Milner Therapeutics Institute ... as a partner to the Milner Therapeutics Consortium. Pfizer ... efficient transfer of materials between industry and academia and ...
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
Breaking Medicine Technology: